News

Carbios inks €7m collaboration
Enlarge image

FundingFrance

Carbios inks €7m collaboration

15.04.2013 - French green plastics company Carbios has secured exclusive patent rights from a collaboration with the National Institute for Agricultural Research.

The five-year collaboration of Carbios (Clermon-Ferrant) and INRA (Paris) at the Toulouse White Biotechnology (TWB) research centre is part of the €22m THANAPLAST™ private-public consortium on plastics, comprising the CNRS, INRA, the Université de Poitiers, Deinove, the Barbier Group, and the Limagrain Group.

 The Carbios-INRA project will focus on the development of bioprocesses for recovering plastic waste and producing economically competitive bio-based polymers. The interdisciplinary collaboration will include R&D staff from TWB, the 3BCar Carnot Institute and two INRA groups. The INRA groups will focus on enzyme screening, enzymatic catalysis and cell engineering.

 Carbios is developing solutions for transforming the global supply of over 100 million tons of plastic waste into a novel, high-quality, renewable raw material for the plastics industry. The company offers a viable economic alternative to the depletion of agricultural resources and the rarefaction of fossil fuels.

Carbios CEO Jean-Claude Lumaret commented that "although Europe generates almost 25 million metric tons of plastic waste each year, only 20% of that is recycled. The recovery of such an important renewable resource is a key business issue. We are delighted to have signed this partnership agreement with LISBP and Micalis - two INRA R&D groups that are internationally renowned for their know-how and expertise in enzymatic bioprocesses. By combining our skills and resources, the resulting synergy will be an impressive driver for innovation and the development of breakthrough industrial bioprocesses".

© eurobiotechnews.eu/pg

http://www.european-biotechnology-news.com/news/news/2013-02/carbios-inks-eur7m-collaboration.html

Stock MarketsIrelandUK

05.03.2015 The IPO wave in the biotech sector shows no signs of slowing down. An Irish life sciences fund set up by former Elan executives plans to raise €325m with its IPO, whilst Summit Therapeutics has announced its IPO pricing of US$34m on Nasdaq.

LicencingDenmark

05.03.2015 Bavarian Nordic is outlicensing its Phase 3 prostate cancer immunotherapy Prostvac to pharma heavyweight Bristol Myers Squibb for a tidy €881m.

BusinessUK

03.03.2015 After weeks of speculation, AstraZeneca has announced its plans to spin out its early-stage antibiotic R&D. The decision marks the company’s aims to “sharpen its focus on three main therapy areas”.

GenericsEUUKHungaryGermanyItalyGreeceAustriaLuxembourgFranceSpain

26.02.2015 It is the first biosimilar monoclonal antibody in many European markets: Mundipharma and Hospira are launching Celltrion’s Remicade generic.

M&AUK

23.02.2015 British drug developer Heptares has been acquired by Japanese biopharma play Sosei for US$400m (€352m).

bioethanolGermanyUKBelgiumFrance

19.02.2015 The price of oil has been sliding for months, and the European bioethanol market is taking it hard. CropEnergies AG has now stopped production at its British unit Ensus UK.

BusinessFranceGermany

17.02.2015 After Christopher Viehbacher’s unceremonious ousting last year, Sanofi has been on the look out for a new CEO. Now, sources say Bayer’s Olivier Brandicourt is set to fill the position.

BusinessUKSwitzerland

12.02.2015 Glaxosmithkline is intent on bolstering its vaccine portfolio further and has bought all shares of Swiss development partner Glycovaxyn.

InvestmentsUKEU

10.02.2015 Interest in biotechnology is on the rise among British investors. Not just one, but two major financiers are planning investment funds in the field.

Events

All Events

Partner-Events

Planegg/Martinsried

1st Munich Biotech Pitch

Berlin (DE)

Proteomic Forum 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • CYTOS1.30 CHF176.60%
  • MEDIGENE4.97 EUR9.23%
  • FORMYCON18.70 EUR7.47%

FLOP

  • VITA 345.30 EUR-5.36%
  • BIOFRONTERA1.98 EUR-4.35%
  • ADDEX3.06 CHF-3.16%

TOP

  • CYTOS1.30 CHF282.4%
  • WILEX3.23 EUR51.6%
  • FORMYCON18.70 EUR25.1%

FLOP

  • MOLOGEN5.13 EUR-16.0%
  • SANTHERA96.10 CHF-12.4%
  • MAGFORCE5.44 EUR-10.8%

TOP

  • SANTHERA96.10 CHF2339.1%
  • WILEX3.23 EUR429.5%
  • FORMYCON18.70 EUR142.9%

FLOP

  • MOLOGEN5.13 EUR-56.7%
  • PAION2.06 EUR-54.6%
  • CYTOS1.30 CHF-54.4%

No liability assumed, Date: 05.03.2015